Enterovirus Vaccine Development
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: 15 February 2025 | Viewed by 2443
Special Issue Editors
Interests: emerging infectious diseases; hand, foot, and mouth disease; establishment of animal models of enterovirus infection; development of vaccines; pathogenesis of enterovirus infection
Interests: epidemiology; drug resistance; oncology; infectious diseases; vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The Enterovirus genus of the Picornaviridae family comprises many important human pathogens, including polioviruses, rhinovirus, enterovirus A71 (EV-A71), EV-D68, Coxsackie virus A6 (CVA6), and CVA16. They cause many mild to life-threatening diseases, such as hand, foot, and mouth disease (HFMD); herpes pharyngitis; and polio. Currently, no effective vaccine is available against enteroviruses except for poliovirus and EV-A71. Although the EV-A71 vaccine has provided a powerful tool for containing HFMD outbreaks, cross-protection against other HFMD-associated enteroviruses has been very limited. Moreover, as the causative spectrum of HFMD has shifted, the prevalence of CVA6, CVA10, and CVA16 has significantly surpassed that of EV-A71. Therefore, vaccines against other pathogens urgently need to be developed.
This Special Issue is intended to cover past and ongoing efforts to develop vaccines against enteroviruses. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but they are not limited to) the following: enterovirus vaccine development; immune efficacy of enterovirus vaccines; and challenges in enterovirus vaccine development.
Dr. Yuefei Jin
Dr. Shuaiyin Chen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- enterovirus
- vaccine
- immune efficacy
- immune response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Deciphering the Evolutionary Dynamics of Coxsackievirus A6 in Shantou, China (2018-2021): A Bioinformatics Approach to Predict Immunological Response Targets via Sequence Homology and Structural Analysis
Authors: Huixiong Deng2, Yanlei Li3, Gefei Wang1,2*, Jinghong Chen4*, Rui Li2*
Affiliation: 1Chaoshan Branch of State Key Laboratory for Esophageal Cancer Prevention and Treatment , Shantou University Medical College, Shantou, Guangdong, 515041, China
2Center of pathogen biology and immunology, Shantou University Medical College, Shantou, Guangdong, 515041, China
3Nursing Research Center, Shantou University Medical College, Shantou, Guangdong, 515041, China
4Shantou Disease Control Center, Shantou, Guangdong, 515041, China
Abstract: The escalating incidence of hand, foot, and mouth disease (HFMD) linked to Coxsackievirus A6 (CVA6) has emerged as a substantial public health concern. To effectively respond to the recent emergence and rapid spread of CV-A6, it is crucial to develop data and tools to understand and monitor its transmission and immune responses. However, information on CV-A6 immune response targets is scarce. In this study, we incorporated CV-A6 viral strains collected from Shantou City from 2018 to 2021, combined with global CV-A6, to investigate the recombination, geographic transmission, and evolutionary characteristics of the CV-A6 epidemic in Shantou City, China. We utilized the Immune Epitope Database and Analysis Resource (IEDB) to catalog existing data related to other enteroviruses, including CV-A16/EV-A71, which share a high sequence similarity with CV-A6 and are the most extensively studied enteroviruses in terms of epitope responses. We identified several regions in CV-A6 that exhibit high homology with other enteroviruses. Potential B-cell and T-cell epitopes of CV-A6 were determined using parallel bioinformatics predictions with various strategies. The identification of the same regions independently by two methods reflects the high probability of these regions serving as immune recognition targets for CV-A6. Finally, we identified evolutionarily constrained conservative candidate epitopes of CV-A6 through sequence Shannon entropy conservation analysis and structure-based network analysis. These predictions can facilitate the design of effective vaccines against this high-priority virus.
